Virbac stock: Virbac targets upper 5.5 to 7.5 percent range for Virbac stock

Published on 10/24/2026 at 05:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Third-quarter revenue reached EUR 400 million on October 19, 2026, up 9.8 percent. Virbac stock has a EUR 2.9 billion market value.

Growth guidance and valuation

Third-quarter revenue reached EUR 400 million on October 19, 2026.
Nine-month revenue totaled EUR 1.168 billion, up 7.9 percent at constant scope.
Virbac had a EUR 2.9 billion market capitalization as of October 23, 2026.

Modernes Pharmawerk für Tiergesundheit in sonniger südfranzösischer Landschaft — Fotorealistische Aufnahme zeigt Veterinärpharma-Anlage von Virbac S.A., passend zu ISIN FR0000031577, moderner Standort Südfrankreich, Illustration mit AI erstellt.

Virbac (ISIN FR0000031577) reported third-quarter revenue of EUR 400 million on October 19, 2026, up 9.8 percent at actual exchange rates from the same period a year earlier, according to MarketScreener. The animal health group said its performance put full-year revenue growth toward the upper end of its 5.5 to 7.5 percent constant-rate and scope guidance.

Nine-month sales accelerate

Revenue for the first nine months reached EUR 1.168 billion, an increase of 7.9 percent at constant exchange rates and scope from the same period in 2025. At actual rates, growth was 5.9 percent because of unfavorable currency effects, while third-quarter organic growth accelerated from 7.2 percent in the second quarter to 8.8 percent, figures published by Boursorama show.

The growth was broad across Virbac's two main businesses. Companion animals grew 8.8 percent at constant rates and scope in the third quarter, while farm animals grew 7.0 percent, according to the company release carried by MarketScreener.

What does guidance mean for margins?

Management kept its adjusted recurring operating income margin outlook at 17 percent at constant rates and scope. The comparison that matters is the 7.9 percent nine-month organic growth rate against the full-year guidance ceiling of 7.5 percent, although the company has not formally raised that range, as MarketScreener reported on October 19, 2026.

Three milestones define the update

On September 17, 2026, Virbac reported first-half revenue of EUR 768 million; on October 6, 2026, its Thailand operation marked 30 years; on October 19, 2026, third-quarter revenue reached EUR 400 million, according to the company's investor calendar and sales release.

Dates and valuation

The next scheduled sales release is January 18, 2027, for fourth-quarter 2026 sales, according to MarketScreener. Virbac had a market capitalization of EUR 2.9 billion as of October 23, 2026, while its 52-week range was EUR 297.00 to EUR 389.50.

Stock context after the update

The last quoted Euronext Paris price was EUR 349.00 on October 23, 2026 at 5:35 p.m. CEST. The company is listed on Euronext Paris in the Pharmaceuticals sector, giving the strong nine-month revenue comparison a direct valuation context.

The further course of trading is shown by the continuously updated real-time quote of Virbac stock.